Trial Profile

A Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BBO 10203 (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Colorectal cancer; HER2 negative breast cancer; HER2 positive breast cancer; Non-small cell lung cancer
Focus Adverse reactions; First in man
Acronyms BREAKER-101
Sponsors BridgeBio Oncology Therapeutics

Most Recent Events

30 Oct 2024 According to a BridgeBio Oncology Therapeutics media release, Dr. Minal Barve is the Principal Investigator of the trial.
30 Oct 2024 According to a BridgeBio Oncology Therapeutics media release, first patient has been dosed with BBO-10203 in the BREAKER-101 trial.
09 Oct 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com